Company ProfilePremium

Sinopharm Tech Holdings Limited

Company Profile Analysis

Ticker: 8156.HK國藥科技股份有限公司

ESOMAR 23 Corporate BadgeISO Certifications Badge
Sinopharm Tech Holdings Limited - Company showcase

Year Founded & Workforce

1999

31 Employees

Sinopharm Tech Holdings Limited logo

Sinopharm Tech Holdings Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Sinopharm Tech Holdings Limited Overview

Sinopharm Tech Holdings is a Hong Kong-headquartered, Cayman-incorporated GEM micro-cap whose only revenue-generating activity is a healthcare-product and pharmaceutical "supply chain services" business — in substance, principal-basis trading of Chinese patent medicines, therapeutic drugs and health products to a highly concentrated set of customers in Hong Kong and Mainland China, conducted partly through a 51%-owned Jiangxi distribution subsidiary. Two legacy segments ("Internet+" solutions and personal protective equipment) are dormant and generated no revenue in FY2025 or FY2026. Management frames the group as an "AI-empowered big-health" platform aligned with Hong Kong's AI+ industrial policy, but no AI revenue, R&D spend or product has been disclosed. The group is balance-sheet distressed — net liabilities of HKD 48.9m, a going-concern material uncertainty, and dependence on its controlling shareholder for liquidity — and since January 2026 has been in breach of the GEM 25% public float requirement. It should be analysed as a restructured shell-like trading business rather than a technology or pharma operator.


Company's own description (Annual Report FY2026, MD&A)

Management states that during FY2026 the group adhered to its core strategy of "technology empowering health" (科技賦能健康), supported by two core businesses — the "big health industry" (大健康產業) and pharmaceutical supply chain services — while using artificial intelligence and big-data technology to accelerate digital transformation. It describes an "AI-driven operating framework" used to assess customer demand, sales trends and inventory, enabling precise procurement and flexible inventory adjustment, and claims to provide customers with efficient, tailored one-stop solutions based on accumulated procurement and supply chain know-how. Through subsidiaries it distributes pharmaceutical and healthcare products in Mainland China.

For FY2026, management acknowledged that supply chain revenue declined significantly owing to changes in the market environment, intensified industry competition and weaker purchasing power, with Mainland retail end-demand recovering more slowly than expected; it responded by optimising the product mix, strengthening negotiation with core brand owners and adjusting regional inventory allocation.

The Directors' Report states the Company's principal activity is investment holding. Note 6 defines three operating segments: (a) "Internet+" solution services; (b) supply chain services — supply chain management, data analysis and related services, trading of related goods, and trading of medical and related products; and (c) manufacturing and distribution of PPE.

Independent characterisation

Stripped of the AI and "big health" framing, the evidence in the FY2026 financial statements describes a small principal-basis wholesale trading operation:

  • 100% of FY2026 and FY2025 revenue is "trading of goods" recognised at a point in time (Note 7). There is no service, subscription, licensing or data-analytics revenue line despite the segment's descriptive name.

  • The group judges itself principal, not agent: it controls goods before transfer, bears inventory risk and has pricing discretion (Note 5). Revenue is therefore recognised gross, which inflates revenue relative to economic value-add.

Gross margin is thin and volatile: (12–14% in FY2022–FY2024 and FY2026; an outlier 23% in FY2025).

Concentration is extreme: five customers accounted for 74.51% of FY2026 sales; five suppliers accounted for ~100% of purchases, the largest 67%; the group bought from only four suppliers in FY2026 (two HK, two PRC) versus nine in FY2025.

Inventory collapsed: from HKD 13.5m (30 Jun 2025) to HKD 0.1m (30 Jun 2026), consistent with back-to-back or order-driven trading rather than stocked distribution.

  • There is no disclosed R&D, no capitalised software, no patents and no technology revenue.

Revenue model mix

Revenue type (FY2026)Share of revenueComment
Product trading (supply chain services segment)100%Point-in-time, principal basis
Services (Internet+ solutions)0%Segment dormant since at least FY2024
Manufacturing (PPE)0%Suspended; operating subsidiary disposed April 2025
Subscription / licensing0%None disclosed

Value-chain position, customers and end-markets

The group sits in the middle of the pharmaceutical/health-product distribution chain: it buys finished Chinese patent medicines, therapeutic drugs and health products from a handful of brand owners/suppliers and resells to trade customers (distributors and retail customers) in Hong Kong and the PRC. Credit terms granted are 30–90 days (up to 180 days for certain customers); supplier credit terms are 30–60 days, although 99% of trade payables at 30 June 2026 (HKD 9.1m of 9.2m) were over one year old, indicating stretched or disputed supplier balances. End-markets are PRC retail pharmacy/consumer health and Hong Kong trade; FY2026 revenue was 57.5% Hong Kong and 42.5% PRC by customer location.

Strategy

Stated strategic themes (Annual Report FY2026)

  1. "Technology empowering health" as the core strategy, anchored by big-health and pharmaceutical supply chain services.

  2. Deeper AI integration into market-trend forecasting, intelligent supply chain management, customer-demand insight and process optimisation.

  3. Regulatory agility in PRC drug distribution: tracking regulation, compliance risk assessments, business stress tests, closer engagement with industry associations and regulators.

  4. Policy alignment with Hong Kong's AI agenda: management cites the HKSAR 2026–27 Budget naming AI a core driver of high-quality development and creating an "AI+ and Industry Development" promotion mechanism; the group positions itself as combining pharma supply chain capability with technological innovation.

  5. New AI+ growth paths under evaluation: digital health platform services, smart logistics solutions, health-tech product R&D, and AI × biotechnology cross-applications, with a "regular progress-evaluation mechanism", stage gates and decision thresholds.

  6. Structural optimisation and talent integration to control administrative and operating costs.

Initiatives in the last 24 months

InitiativeDateDetailMeasurable target
Capital reorganisation + loan capitalisationApproved 8 Aug 2024; completed 15 Nov 2024Eliminated ~HKD 193m of debt; issued 450m shares and 1,480m CPS at HKD 0.1Completed
Exit from non-core segmentsFeb 2025 – May 2026Disposal of Internet+ subsidiary (Feb 2025), PPE subsidiary (Apr 2025), 19.05% Ever Development stake (Jun 2025), two dormant HK subsidiaries (May 2026)Completed
AI-driven supply chain analyticsDescribed FY2025–FY2026Data tools for procurement, inventory and demand analysisNone disclosed; no capex or R&D spend disclosed
M&A governance reformProposed FY2026Protective deal terms (escrow, deferred payment, asset pledges) and monitoring mechanisms for future acquisitionsPolicy only
Internal-control upgrade on disposalsFrom Dec 2024Checklist, board approval, pre-audit copies of records before hand-over, auditor consultationResponse to FY2024 qualified opinion
Comprehensive internal-control reviewExpected by end-2026Stated in FY2026 CG reportPending
Recovery of Hero Global compensationDemand 24 Aug 2026; legal letter 9 Sep 2026Pursuit of HKD 75.6m outstandingPossible litigation

Guidance and medium-term targets

No financial guidance, revenue targets, margin targets or capital-allocation targets are published. As at the FY2026 report date the directors had no plans for material investments or capital assets and no capital commitments. ESG targets are limited to holding emissions, waste density and electricity intensity at or below FY2020 baseline levels.

Products & Services

The group discloses no named brands, SKUs, platforms, pricing schedules or launch dates. The catalogue below is therefore built from segment descriptions and is complete to the extent disclosed.

Sources: Annual Report FY2026 (MD&A, Note 6, Note 7); Annual Report FY2025 (Directors' Report on Hero Global activities).

The company's ESG report adds that before launching any new product it requires samples from suppliers or factories and engages third-party professionals for quality-control checks, and that a dissatisfied customer may be offered a replacement "combination" (組合) of products — suggesting some sales are packaged product bundles.

Product Portfolio

SegmentOfferingDescription / capabilities (as disclosed)Target customerLaunch / latestPricing modelFlagship named offering

Supply chain services

Trading of Chinese patent medicines and therapeutic drugs

Procurement from brand owners and resale; regional inventory allocation across PRC provinces

PRC distributors and retail pharmacy customers

—

Per-transaction sales contract, credit 30–90 days

—

Supply chain services

Trading of health / "big health" products

Health products sourced from a concentrated supplier base

HK and PRC trade customers

—

Per-transaction

—

Supply chain services

"Supply chain management, data analysis and related services"

Described as AI-driven demand, sales-trend and inventory analysis embedded in trading

Same customers (bundled)

AI integration described from FY2025

No separate revenue recognised

—

Internet+ solution services

Internet-related solutions (legacy Hero Global: consulting, blockchain, big data, e-commerce payment/membership/precision marketing tools)

Dormant

Previously PRC online platforms and Sino-TCM

Acquired 2019; suspended

——

PPE

Manufacture and distribution of PPE and consumables

Suspended after COVID demand normalised

—

c.2020; suspended

——

Planned (not launched)

Digital health platform services; smart logistics solutions; health-tech product R&D; AI × biotech applications

Stated as exploration paths with stage-gate evaluation

Not specified

Not launched

——

“—” = not publicly disclosed.

Financial Narrative

All figures HKD millions, fiscal years ended 30 June. Primary source: Five-Year Financial Summary and consolidated statements, Annual Report FY2026; attributable net income FY2022–FY2024 and FY2022–FY2024 balance-sheet line items from S&P Global data via StockAnalysis (secondary). Derived metrics computed by the analyst.

Per-share data

Data-quality flag. The FY2026 accounts use the same weighted-average share count (464.789m) as FY2025, even though 633.69m ordinary shares were in issue throughout FY2026 (the 450m loan-capitalisation shares were issued 15 Nov 2024). On 633.69m shares, FY2026 basic loss per share would be ≈ −1.44 HK cents. No dividend was declared in FY2024, FY2025 or FY2026; the company has had no distributable reserves in the period reviewed.

Margins and growth

Revenue CAGR FY2022–FY2026: ≈ 2.7% per year (HKD 41.0m → 45.6m), effectively flat across the cycle, with the FY2025 surge fully reversed in FY2026.

Half-year phasing (derived)

H1 FY2026 per interim results (26 Feb 2026: revenue HKD 26.769m, +41.65% YoY; attributable loss HKD 3.681m, narrowed 33.23%); other halves derived. H2 FY2025 "profit" reflects one-off gains on subsidiary disposals (HKD 6.9m) and loan capitalisation (HKD 3.9m).

The phasing shows a sharp deterioration in the second half of FY2026: revenue fell to HKD 18.8m against HKD 42.4m in the prior-year second half, with no offsetting one-off gains.

Balance sheet

FY2022–FY2024 working-capital line items: S&P via StockAnalysis. Goodwill (HKD 12.3m at FY2021) was fully impaired by FY2022; MD&A FY2025 confirms goodwill and intangibles remain fully impaired.

Debt and liquidity

Source: Annual Report FY2026 Note 36 (reconciliation of financing liabilities); MD&A FY2025/FY2026. FY2024 net current liabilities derived from MD&A current assets HKD 38.1m and current liabilities HKD 249.4m. FY2024 short-term classification reflects that all debt was overdue/on demand.

Gearing inconsistency. The company defines gearing as interest-bearing borrowings ÷ total assets. On that definition, FY2026 shareholder loans alone (HKD 22.4m) equal ~100% of total assets, and including the CPS liability ~237%. The reported 75.8% cannot be reconciled to disclosed balances; the reported FY2025 figure of 9% likewise appears to exclude shareholder loans and the CPS liability.

Cash flow

FY2025–FY2026 from Annual Report FY2026 cash flow statement; FY2022–FY2024 from S&P via StockAnalysis; FY2024 shareholder advances = Quantum drawdowns of HKD 10m (8 Nov 2023) and HKD 5m (1 Feb 2024).

FY2026 operating cash outflow (HKD 4.0m) was cushioned by a HKD 3.1m working-capital release — inventory down HKD 13.4m and receivables down HKD 12.6m, offset by a HKD 22.8m reduction in payables and accruals. Before working capital, operations consumed HKD 6.9m. The group repaid the bank loan (HKD 3.3m) and the residual Creative Big borrowing (HKD 1.6m), funded by HKD 8.0m of new Quantum advances at 5%.

Ratios

Not meaningful: ROE and debt/equity (negative equity throughout FY2022–FY2026); ROIC (negative invested capital); net debt/EBITDA in FY2022, FY2023 and FY2026 (negative EBITDA). Net debt/EBITDA was ≈ 39.4x in FY2024 and ≈ 6.5x in FY2025.

Commentary on trends, inflections and drivers

Revenue. Revenue was stuck at HKD 41–43m in FY2022–FY2024, surged 48% in FY2025 on what management called higher demand for healthcare products and improved supply chain efficiency, and fell back 26% in FY2026 amid weak PRC retail demand and price competition. The PRC subsidiary's revenue more than halved (HKD 42.9m → 19.4m), while Hong Kong revenue rose 43% (HKD 18.4m → 26.2m). Revenue therefore depends on a few customer relationships, and swings by tens of percent with the loss or gain of a single account (Customer D and Customer E, each ~HKD 6.7m in FY2025, did not appear above the 10% threshold in FY2026, while Customer C at HKD 12.4m appeared).

Earnings quality. In every year from FY2022 to FY2025 the reported bottom line was dominated by non-operating items: large "other income and gains" (HKD 39.4m, 106.8m, 18.1m, 10.8m) largely from disposals, profit-guarantee compensation and debt-restructuring gains; and large impairments (HKD 58.6m in FY2022, 74.8m in FY2023, chiefly the Hero Global compensation receivable). FY2026 is the first "clean" year with few one-offs (other income HKD 1.4m, mainly the write-back of stale payables and contract liabilities), and it shows the underlying run-rate: a core operating loss of ~HKD 8m on ~HKD 46m of revenue.

Cost base. Administrative expenses have been cut by 76% in four years (HKD 41.4m → 9.9m) and headcount is down to 31. The FY2026 tripling of selling and distribution costs while revenue fell is unexplained in the filings and is the main driver of the core-loss widening.

Balance sheet inflection. The November 2024 loan capitalisation was the decisive event: total liabilities fell from HKD 250m to HKD 88m and the deficit from HKD 206m to HKD 37m. However, the deficit widened again to HKD 48.9m in FY2026 as losses resumed, and the CPS created a new liability component (HKD 30.7m) carrying 5% preferred distributions (HKD 7.4m per year for five years), which the company has deferred.

Liquidity. Cash of HKD 5.6m against current liabilities of HKD 55.4m; operating cash burn of ~HKD 4–6m per year; survival depends on the controlling shareholder's undertaking (dated 17 Aug 2026) not to demand repayment for 18 months, and on discretion to defer CPS distributions for up to 10 years.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Overview

SegmentContentsStatus

"Internet+" solution services

Internet-related solution services; legacy of Hero Global (business management/consulting re "Internet Plus", blockchain, big data, e-commerce technology)

Dormant; no revenue FY2024–FY2026; principal subsidiary Sinopharm Health Cross-border E-Commerce disposed Feb 2025

Supply chain services

Supply chain management, data analysis and related services; trading of related goods; trading of medical and related products

Sole revenue source

Manufacturing & distribution of PPE

Manufacture and sale of PPE, consumables and related goods (COVID-era)

Suspended; Sinopharm (Hong Kong) Industrial disposed Apr 2025

Segment revenue (HKD Mn)

Segment revenue (HKD Mn)FY2024FY2025FY2026

Supply chain services

41.361.25345.582

Internet+ solution services

000

PPE manufacturing & distribution

000

Total revenue

41.27761.25345.582

Revenue by Segment

Segment result (HKD Mn)FY2025FY2026

Supply chain services

-0.931-5.950

Internet+ solution services

-0.0040.022

PPE manufacturing & distribution

-0.797-0.015

Total segment loss

-1.732-5.943

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment Margins & Growth (%) and Revenue by Segment (%)

MetricFY2024FY2025FY2026

Supply chain revenue YoY growth (%)

—48.4-25.6

Supply chain gross margin (%)

122314

Supply chain segment result margin (%)

—-1.5-13.1

Supply chain share of group revenue (%)

100100100

Group Entities

EntityPlace of incorporation / operationPaid-up capitalGroup interestActivity

China Success Enterprises Limited

BVI / Hong Kong

USD 2,000

100% (direct)

Investment holding

Sinopharm Tech Corporate Management Limited (國藥科技企業管理有限公司; formerly China Vanguard Corporate Management Ltd)

Hong Kong

HKD 20,000,000

100% (direct)

Investment holding; purchaser under Hero Global SPA

弘名有限公司 (English name not stated in Chinese report)

Hong Kong

HKD 1

100% (indirect)

Distribution of PPE

天渝有限公司 ("Tianyu")

BVI / Hong Kong

USD 100

57% (indirect)

Investment holding

江西鷺嶼 ("Jiangxi Luyu")

PRC (limited liability)

RMB 10,000,000

51% (indirect)

Distribution of medical products

Income Statement

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (HKD Mn)

40.98542.83941.27761.25345.582

Cost of sales (HKD Mn)

35.05337.36936.25847.02239.161

Gross profit (HKD Mn)

5.9325.4705.01914.2316.421

Other income and gains (HKD Mn)

39.350106.84918.08510.8431.366

Impairment losses on receivables and other assets, net (HKD Mn)

58.55474.7822.5878.4260.883

Selling and distribution expenses (HKD Mn)

1.0032.2510.4951.6484.685

Administrative and operating expenses (HKD Mn)

41.43119.77513.68711.2859.902

Core operating result: GP less S&D and admin (HKD Mn)

-36.502-16.556-9.1631.298-8.166

EBIT: pre-tax loss plus finance costs (HKD Mn)

-77.748-2.8363.6014.775-7.683

Depreciation and amortisation (HKD Mn)

2.4002.0101.3801.3331.228

EBITDA (HKD Mn)

-75.348-0.8264.9816.108-6.455

Finance costs (HKD Mn)

16.4108.57123.9335.8544.007

Loss before tax (HKD Mn)

-94.158-11.407-20.332-1.079-11.690

Income tax (charge)/credit (HKD Mn)

0.3871.307-0.083-0.291-0.213

Loss for the year (HKD Mn)

-93.771-10.100-20.415-1.370-11.903

Loss attributable to owners (HKD Mn)

-88.000-10.640-19.700-0.867-9.142

Per-Share Data and Share Count (millions)

MetricFY2025FY2026

Basic and diluted loss per share (HK cents)

-0.19-1.97

Weighted average ordinary shares used (millions)

464.789464.789

Dividends per share (HK cents)

00

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue growth YoY (%)

—4.52-3.6548.39-25.58

Gross margin (%)

14.4712.7712.1623.2314.09

Core operating margin (%)

-89.06-38.65-22.202.12-17.92

EBIT margin (%)

-189.70-6.628.727.80-16.86

EBITDA margin (%)

-183.84-1.9312.079.97-14.16

Net margin, attributable (%)

-214.71-24.84-47.73-1.42-20.06

Income Statement (Half-Yearly)

Metric (HKD Mn)H1 FY2025H2 FY2025H1 FY2026H2 FY2026

Revenue

18.89842.35526.76918.813

Loss attributable to owners

-5.5134.646-3.681-5.461

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (HKD Mn)

76.88633.48244.49051.73622.439

Total liabilities (HKD Mn)

250.283213.236250.08988.43071.319

Net liabilities / total deficit (HKD Mn)

-173.397-179.754-205.599-36.694-48.880

Capital deficiency attributable to owners (HKD Mn)

-166.777-172.733-199.480-36.868-46.404

Non-controlling interests (HKD Mn)

-6.620-7.021-6.1190.174-2.476

Cash and bank balances (HKD Mn)

2.991.782.646.9465.617

Trade receivables, net (HKD Mn)

28.428.1020.0318.1255.715

Inventories (HKD Mn)

1.350.863.5413.4810.118

Total current assets (HKD Mn)

48.0827.0538.0749.13320.965

Property, plant and equipment (HKD Mn)

4.651.163.882.0751.474

Goodwill and intangibles (HKD Mn)

00000

Balance Sheet and Margin Analysis (%)

MetricFY2024FY2025FY2026

Other borrowings incl. Creative Big (HKD Mn)

71.9331.5570

Bank borrowings (HKD Mn)

03.2830

Amounts due to shareholders (HKD Mn)

125.49013.77322.367

CPS liability component (HKD Mn)

027.45530.731

Lease liabilities (HKD Mn)

1.3230.6650

Total debt incl. CPS liability (HKD Mn)

198.74646.73353.098

Short-term portion (HKD Mn)

198.74626.68037.168

Long-term portion (HKD Mn)

020.05415.930

Net debt (HKD Mn)

196.10639.78747.481

Net current liabilities (HKD Mn)

-211.3-19.243-34.424

Company-reported gearing ratio (%)

162975.8

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (HKD Mn)

-36.764.73-9.25-5.697-4.022

Capital expenditure (HKD Mn)

0.1203.3300

Free cash flow (HKD Mn)

-36.894.73-12.58-5.697-4.022

Financing cash flow (HKD Mn)

32.24-4.5214.989.9843.073

Shareholder advances received (HKD Mn)

0015.09.08.0

Dividends paid (HKD Mn)

00000

Share buybacks (HKD Mn)

00000

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2022FY2023FY2024FY2025FY2026

ROA, attributable loss / year-end total assets (%)

-114.5-31.8-44.3-1.7-40.7

Asset turnover, revenue / year-end assets (x)

0.531.280.931.182.03

Interest coverage, EBIT / finance costs (x)

-4.74-0.330.150.82-1.92

Current ratio (x)

——0.150.720.38

Ratio

FY2025

FY2026

———

Days sales outstanding (days)

108.045.8———

Days inventory outstanding (days)

104.61.1———

Days payables outstanding (days)

178.185.4———

Cash conversion cycle (days)

34.5-38.5———

Region revenue (HKD Mn)

Region revenue (HKD Mn)FY2025FY2026

PRC (Mainland China)

42.87719.355

Hong Kong

18.37626.227

Total

61.25345.582

Region growth and mix (%)

Region growth and mix (%)FY2025FY2026

PRC share of revenue (%)

70.042.5

Hong Kong share of revenue (%)

30.057.5

PRC revenue growth YoY (%)

—-54.9

Hong Kong revenue growth YoY (%)

—42.7

Capital Markets

ItemValueSource / date

Last price

HKD 0.159

StockAnalysis, 9 Oct 2026

Prior observed price

HKD 0.209 (10 Sep 2026); HKD 0.163 (29 Jul 2026)

StockAnalysis

52-week range

HKD 0.148 – 0.355

StockAnalysis (as of Sep 2026)

Beta

1.69

StockAnalysis

Loan-capitalisation issue price

HKD 0.10 (Nov 2024); closing price on agreement date HKD 0.123 (14 Jun 2024)

Annual Report FY2025

1/3/5-year total return

Not publicly disclosed in sources reviewed; series distorted by the 25:1 consolidation (29 Aug 2023) and ~HKD 0.1 dilutive issuance

—

Typical daily volume

Very thin (e.g., 1,400 shares on 10 Sep 2026)

StockAnalysis

Valuation Multiples

MultipleBasic (ordinary shares only)Fully converted (CPS as equity)

Market capitalisation (HKD Mn)

100.8336.1

Enterprise value (HKD Mn)

148.3 (mkt cap + shareholder loans 22.4 + CPS liability 30.7 − cash 5.6)

352.9 (mkt cap + shareholder loans 22.4 − cash 5.6)

EV / Sales FY2026 (x)

3.257.74

EV / EBITDA

n/m (negative EBITDA)

n/m

P/E

n/m (loss)

n/m

P/B

n/m (negative equity)

n/m

Capital Markets (Annual)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per ordinary share (HKD)

00000

Share buybacks (HKD Mn)

00000

Analyst Conclusions

Management guidance and consensus

Management offers only qualitative confidence ("full of confidence in business prospects") and an AI+ exploration agenda; no quantitative guidance. Analyst coverage: none with published estimates (Simply Wall St records zero analysts submitting estimates); consensus growth expectations are not available.

Bull case

  1. Hero Global recovery is a step-change asset. The HKD 75.6m outstanding compensation exceeds the group's HKD 48.9m net deficit; even partial recovery through litigation would restore positive equity — and has a carrying value of essentially nil, so any recovery is pure upside.

  2. Controlling-shareholder alignment. Mr. Yam holds 74% of the votes and HKD 93m of CPS; he has funded the group repeatedly and capitalised debt at HKD 0.1. A controller with that much at stake is incentivised to inject assets or recapitalise rather than let the listing lapse.

  3. Operating leverage on a tiny cost base. At FY2025-like volume (HKD 61m) and margin (23%), the HKD 14.6m combined S&D and admin cost base is roughly covered; a single new large customer could swing the core result back to break-even.

Bear case

  1. Going concern rests on one person. With HKD 5.6m of cash, HKD 34.4m of net current liabilities and ~HKD 4–7m of annual operating burn, survival depends on Mr. Yam's continued support; the 18-month standstill expires around February 2028.

  2. The FY2025 recovery was not durable. FY2026 revenue −26%, gross margin back to 14%, H2 revenue down 56% YoY; one-off gains masked the run-rate in FY2023–FY2025, and the clean FY2026 run-rate is a HKD 8m core loss.

  3. Governance and disclosure deficits. No chair/CEO, three auditors and three company secretaries in two years, qualified opinions, a public-float breach inconsistent with earlier monthly-return confirmations, and multiple numerical errors in the FY2026 annual report raise the risk of further regulatory action, including suspension.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableTimingWhy it matters
Public float restoration (placing or sell-down)OngoingProlonged breach risks suspension; restoration also unlocks CPS conversion
AGM (rotation of Ms. Kwok and Mr. Lau; reappointment of Suya WWC)Expected ~Dec 2026Board continuity
Q1/interim trading (six months to 31 Dec 2026)Interim results ~Feb 2027Tests whether the H2 FY2026 revenue collapse persists
Legal action vs. Hero Global vendorFrom Sep 2026Potential HKD 75.6m recovery
Comprehensive internal-control reviewBy end-2026Remediation of governance flags
Any asset injection, placing or CPS redemption/conversionUnscheduledCapital-structure reset
Customer concentration (Customers A and C)Ongoing~57% of revenue
CPS distribution arrears (HKD 14.8m)Due 31 Dec 2027Liquidity and dividend blocker

Analyst verdict

Sinopharm Tech Holdings is best understood not as a healthcare-technology company but as a restructured GEM listing housing a small, loss-making, highly concentrated pharmaceutical and health-product trading operation. The November 2024 loan capitalisation was genuinely transformative — it removed ~HKD 193m of overdue convertible-bond and shareholder debt and averted the existential threat posed by the 2023 winding-up petition — yet two years on, the business has not demonstrated a self-sustaining model. FY2026 data are unambiguous: revenue fell 26% to HKD 45.6m, gross profit more than halved, the core operating loss reached ~HKD 8m, and net liabilities widened to HKD 48.9m, all without the one-off gains that flattered FY2023–FY2025.

The AI narrative is unsupported by any disclosed spending, IP or revenue, and should carry no valuation weight until the company reports a funded, measurable initiative. The governance record — no chair or CEO, frequent auditor and secretary changes, qualified opinions, an unremedied public-float breach, and visible errors in the FY2026 annual report — calls for a meaningful discount and heightened scrutiny of every reported figure.

The equity's value therefore rests on two options rather than on operations: (i) recovery of the HKD 75.6m Hero Global compensation, which is credit-impaired to nil and depends on the vendor's solvency and willingness to pay; and (ii) the controlling shareholder's intentions for the listed platform, given his 74% voting control and large CPS position. At ~HKD 148m basic EV against negative EBITDA, the market is already pricing a material probability of a corporate action.

Verdict: a speculative special situation, not an investable operating business. Monitor float restoration, the Hero Global claim, and H1 FY2027 trading; absent a recapitalisation or asset injection, the base case is continued losses and dependence on shareholder funding.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleAgeAppointedBackground / educationFY2026 total emoluments (HKD K)

Mr. CHIU Sin Nang Kenny (趙善能)

Executive Director; authorised representative; member, Remuneration and Nomination Committees

64

2 Jun 2025

FCPA (HK and Australia), 35+ years in financial accounting and corporate management; NED of China Changbaishan International (formerly Hua Yin International, 0989); director, Hong Kong International Family Office Ltd; former ED of Kin Shing Holdings (1630); former INED of Keyne (0009), Sincere Watch (0444), Baijin Life Science (1466), Coolpad (2369), Kingston Financial (1031). MAcc (CUHK), EMPAcc and CFO certificate (Shanghai National Accounting Institute), MCom (UNSW), LLB (Peking University), BAS and BA Econ (York University). Criticised by the HKEX Listing Committee (regulatory announcement 9 May 2023) over his tenure as Keyne INED. Beneficial owner of Creative Big Limited (547.6m CPS).

60

Ms. KWOK Shuk Yi (郭淑儀)

Executive Director; authorised representative; member, Remuneration and Nomination Committees

50

Joined Jul 2008; ED 5 Sep 2022

BBA (RMIT, distinction; FY2025 report states Bachelor in HR Management); council member, Guangdong AI Industry Association; "AI Enterprise Management Expert" and chair, Shenzhen AI Industry Association; 20+ years senior management; responsible for overall operations and strategy

726 (fees 60; salary 648; pension 18)

Mr. LAU Fai Lawrence (劉斐)

INED; Chair of Audit, Remuneration and Nomination Committees

55

Jan 2020

Practising CPA (HK); BBA (HKU 1994), MCorpFin (PolyU 2007); ED of Hengxin Technology (1085) since Jul 2025; company secretary of BBMG (2009) and HM International (8416); joint company secretary of Huanxi Media (1003) since Aug 2026; INED of China Ecotourism (1371); numerous prior directorships, several at companies later delisted

60

Mr. HEUNG Pik Lun (向碧倫)

INED; member of all three committees

64

Sep 2023

20+ years in PRC/HK business; former ED of Master Glory Group (275, delisted Feb 2021); Royal Chartered Surveyor; holds 3.92m ordinary shares (0.62%)

60

刁志強 (English name not stated in report reviewed)

INED; member of all three committees

66

19 Dec 2025

30+ years in AI, semiconductors, wireless and multimedia; former VP, Qualcomm (internet business development, China smartphone ecosystem); former VP Communications Technology and R&D Director, ASTRI; founder of Bitzmo Inc. (UWB semiconductors, Silicon Valley); prior roles at Cadence, National Semiconductor, TRW; adviser to HK Science Park and Bryan, Garnier & Co; BS/MS EE, Cornell

80

余秉明 (English name not stated in report reviewed)

INED; member of all three committees

65

19 Dec 2025

Director of PAS Company Limited since Jun 2002; sales and marketing background; former INED of Hang Fu Holdings (0643) Aug 2022–Feb 2023

80

Governance Overview

AttributeStatus (FY2026)

Board size

6 (2 ED, 0 NED, 4 INED) after 19 Dec 2025

Independence

4 of 6 (67%)

Chair / CEO

No chairman or CEO appointed; both roles exercised collectively by the executive directors — deviation from CG Code C.2.1

Committees

Audit (4 INEDs, chaired by Lau); Remuneration (6 members, chaired by Lau); Nomination (6 members, chaired by Lau since 19 Dec 2025)

Board meetings FY2026

6 (FY2025: 11)

Board evaluation

Not conducted in FY2026 (required at least biennially under CG Code B.1.4); scheduled for FY2027

Gender diversity

1 female director of 6; workforce 58% male / 42% female

Service contracts

None; directors subject to rotation

Major Shareholders

HolderOrdinary shares% of ordinaryCPS (non-voting)CPS as % of ordinaryUltimate owner

Integrated Asset Management (Asia) Ltd ("IAM") and concert parties

321,694,52050.77932,541,460147.16

Mr. YAM Tak Cheung (任德章)

Quantum Worldwide Investment Ltd

150,000,00023.6700

Mr. YAM Tak Cheung

Creative Big Limited

00547,609,59086.42

Mr. CHIU Sin Nang Kenny (ED)

Mr. HEUNG Pik Lun (INED)

3,920,0000.6200—

Ms. KWOK Shuk Yi (ED) — options

1,600,000 (options)

0.25———

Mr. LAU Fai Lawrence (INED) — options

160,000 (options)

0.03———

Public

≈158,078,535

≈24.95

———

Competitive Landscape

Key Competitors

CompetitorListingRelevanceScale indicator

Sinopharm Group Co. Ltd.

1099.HK

Largest PRC pharma distributor

FY2025 revenue RMB 575.2bn (−1.6%); attributable profit RMB 7.16bn

Shanghai Pharmaceuticals Holding

2607.HK / 601607.SS

National distributor and manufacturer

≈USD 38bn sales (Forbes Global 2000, 2025)

China Resources Pharmaceutical Group

3320.HK

National distributor

≈USD 35.8bn sales (Forbes Global 2000, 2025)

Jointown Pharmaceutical Group

600998.SS

Private national distributor

—

China Traditional Chinese Medicine Holdings

0570.HK

Sinopharm-group TCM platform; overlaps in Chinese patent medicine

—

Sinopharm Accord

000028.SZ

Sinopharm-group regional distribution/retail

H1 2025 revenue RMB 36.8bn

Yixintang / LBX / Dashenlin (PRC pharmacy chains)

Shenzhen/Shanghai

Downstream buyers with direct sourcing

—

Regional Jiangxi wholesalers (unlisted)

—

Direct local competition for Jiangxi Luyu

—

HK health-product traders (e.g., small GEM/Main Board issuers)

Various

Competition for HK trade customers

—

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricSinopharm Tech (8156) FY2026Sinopharm Group (1099) FY2025Shanghai PharmaCR Pharma

Revenue

HKD 45.6m

RMB 575.2bn

≈USD 38bn

≈USD 35.8bn

Revenue growth

−25.6%−1.6%——

Gross margin

14.1%7.2%——

Operating margin

−16.9% (EBIT)

3.0%——

Net margin

−20.1%1.2%——

Employees

31

≈94,910

——

Company Snapshot

$5.9M

Revenue

31

Employees

1999

Founded

Central, Hong Kong

Headquarters

SWOT Analysis

Strengths

  • Debt overhang largely removed: loan capitalisation eliminated ~HKD 193m of debt in Nov 2024, cutting total liabilities from HKD 250.1m (FY2024) to HKD 88.4m (FY2025).
  • Committed controlling shareholder: Mr. Yam's entities advanced HKD 9m (FY2025) and HKD 8m (FY2026) and gave an 18-month repayment standstill on 17 Aug 2026.
  • Lean cost base: administrative expenses down from HKD 41.4m (FY2022) to HKD 9.9m (FY2026); headcount 31.
  • No external bank debt: bank loan and Creative Big borrowing fully repaid in FY2026; no pledged assets or contingent liabilities.
  • Flexible CPS terms: preferred distributions can be deferred up to 10 years and the CPS are perpetual with no holder put — they are equity-like from a liquidity standpoint.
  • Demonstrated ability to scale volume: revenue rose 48% in FY2025 to HKD 61.3m with a 23% gross margin, showing the platform can absorb larger orders.

Weaknesses

  • Negative equity: net liabilities HKD 48.9m and net current liabilities HKD 34.4m at 30 Jun 2026; going-concern material uncertainty flagged by the auditor.
  • Extreme concentration: top-5 customers 74.5% of sales; top-5 suppliers ~100% of purchases, largest 67% (FY2026).
  • Persistent core losses: core operating result negative in four of five years (FY2026: −HKD 8.2m).
  • Disclosure quality: FY2026 MD&A describes a 26% revenue decline as "growth" and misstates prior-year gross profit; EPS uses an outdated share count; top-customer share (34.81%) disagrees with Note 6 (Customer A = 30.4%); company-reported gearing cannot be reconciled.
  • No technology substance: no R&D, IP or tech revenue despite the "Tech" and AI branding.
  • Leadership vacuum: no chairman or CEO; executive roles shared by two EDs; finance-function turnover (three company secretaries since Jun 2025).

Opportunities

  • HKD 75.6m Hero Global compensation claim: any recovery would exceed the group's entire net-liability position (HKD 48.9m); legal letter issued 9 Sep 2026.
  • HK AI+ policy support (2025 Policy Address; 2026–27 Budget AI+ mechanism) could open grant or partnership channels for health-tech pilots.
  • Board technology expertise: new INED with Qualcomm/ASTRI semiconductor and AI background could support credible AI+ initiatives.
  • Hong Kong revenue momentum: +42.7% in FY2026 to HKD 26.2m, partially offsetting PRC weakness.
  • Shell and listing-platform value: a clean GEM listing with a reduced liability base may attract asset injections from the controlling shareholder (speculative; nothing announced).
  • Recapitalisation optionality: the company can redeem CPS at HKD 0.1 at its discretion, or holders can convert subject to float restoration, simplifying the capital structure.

Threats

  • Public float breach since 14 Jan 2026: prolonged non-compliance can lead to trading suspension under GEM Rules.
  • Shareholder funding dependency: amounts due to shareholders rose to HKD 22.4m; withdrawal of support would likely be terminal.
  • PRC demand and pricing pressure: PRC revenue −54.9% in FY2026; industry leaders also shrinking.
  • Customer loss risk: two customers accounted for ~57% of FY2026 revenue.
  • Recovery risk on receivables: trade receivable ECL allowance of HKD 11.0m against gross HKD 16.7m; 85.6% loss rate on balances over 365 days; the KAM in the auditor's report.
  • Accumulating CPS arrears: HKD 14.8m of deferred preferred distributions due by 31 Dec 2027; the dividend blocker prevents any ordinary distribution until paid.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Apr 2025Disposal of Sinopharm (Hong Kong) Industrial (PPE) for HKD 1,000Exit PPE; HKD 7.1m gain on release of net liabilities
2 Jun 2025Mr. Chiu Sin Nang Kenny appointed ED and joins Remuneration and Nomination Committees; Ms. Kwok leaves Nomination CommitteeCPS holder Creative Big's owner enters the board; disclosure of his 2023 HKEX criticism
12 Jun 202519.05% of Ever Development sold to Grace Fortune for ~HKD 3.6m (non-cash novation)Discloseable transaction; removes last equity investment
13 Jun 2025Mr. Ho Kam Kin resigns as ED and company secretary; Ms. Wong Chi Ling appointed company secretary; Mr. Chiu becomes authorised representativeFinance-function turnover
24 Jun 2025SFAI resigns as auditor; Suya WWC appointedThird auditor in ~10 months
FY2025 (to Jun 2025)Quantum advances HKD 9m under HKD 12m facilityContinued reliance on controlling shareholder
26 Sep 2025FY2025 results: revenue +48% to HKD 61.3m; GP +184%; attributable loss narrows 95% to HKD 0.9mBest result in years, aided by one-offs
26 Sep 2025Board defers first CPS preferred distribution (HKD 7.4m, due 15 Nov 2025) to 31 Dec 2026Liquidity preservation
26 Sep 2025FY2025 audit opinion qualified on comparatives (FY2024 disposed-subsidiary records)Governance flag
23 Oct 2025Company secretary changes to 郭祖貽Second change in five months
10 Dec 2025Directors attend 2-hour legal-counsel seminar under GEM Rule 5.02GCompliance
19 Dec 2025AGM: Dr. Cheng retires; Mr. Hsu resigns; INEDs 刁志強 and 余秉明 elected; committees reconstituted (Lau chairs Nomination)Board refresh; tech expertise added
14 Jan 2026Public float falls below 25% (non-public holders reach ≈75.05%)GEM Rule breach; likely triggered by INED Heung's acquisition of 3.92m shares (inferred: his holding first appears in the FY2026 register)
5 Feb 2026January 2026 monthly return confirms 25% public-float complianceInconsistent with the later disclosure of non-compliance from 14 Jan 2026
26 Feb 2026Interim results: revenue HKD 26.8m (+41.65%); attributable loss HKD 3.7m (−33%)H1 looked like a recovery
FY2026New Quantum advances HKD 8m at 5%Shareholder-funded liquidity
FY2026Repayment of bank loan (HKD 3.3m) and Creative Big residual borrowing (HKD 1.6m)External bank debt eliminated
May 2026Disposal of Fenglin International (50%, HKD 1) and Guoke Technology (99.9%, HKD 999)Clean-up of dormant entities
30 Jun 2026Year-end inventory down to HKD 0.1m from HKD 13.5mTrading volume contraction
17 Aug 2026Letters of undertaking from IAM and Quantum: no repayment demand for 18 monthsBasis for going-concern assumption
24 Aug 2026Demand letter to Hero Global vendor for HKD 75.6m outstanding compensationPotential litigation
9 Sep 2026Legal letter issued to vendor via legal advisersEscalation
16 Sep 2026Announcement on public float shortfall and remedial measuresRegulatory exposure
24 Sep 2026FY2026 results: revenue −26% to HKD 45.6m; GP −55%; attributable loss HKD 9.1m; net liabilities HKD 48.9m; going-concern material uncertaintyReversal of FY2025 recovery
24 Sep 2026Board defers both first and second CPS distributions (HKD 7.4m each) to 31 Dec 2027Accumulating preferred arrears HKD 14.8m
24 Sep 2026Auditor unmodified opinion with MURGC; KAM on receivables ECLImprovement from FY2025 qualification
29 Sep 2026Annual Report FY2026 published—
7 Oct 2026Revised monthly returns filed for Apr–Aug 2026 plus Sep 2026 returnLikely corrections to public-float confirmations

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

5 charts
Income Statement: Revenue & Gross Profit: Revenue rose from HKD 41 Mn in FY2022 to HKD 45.6 Mn in FY2026.
Sinopharm Tech Holdings Limited — Income Statement: Revenue & Gross Profit
Series (HKD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue4142.841.361.345.6
Cost of sales35.137.436.34739.2
Gross profit5.95.5514.26.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.